CONTENT HUB

Latest news

Here, you will find announcements, advancements in synthetic DNA technology, and insights into our contributions to the fields of vaccines, gene therapy, cell therapy and gene editing

Jennifer Gelman 08/01/2026 Jennifer Gelman 08/01/2026

4basebio to present at Biotech Showcase 2026

08 JAN 2026

Press release: 4basebio PLC (AIM: 4BB) announced that it is presenting at Biotech Showcase™ 2026. This year, registered attendees can view 4basebio presentation live. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

Jennifer Gelman 27/10/2025 Jennifer Gelman 27/10/2025

4basebio synthetic opDNA® utilised in PhaseI/II US clinical

27 OCT 2025

Press release: Global pharma partner initiates mRNA therapy trial using 4basebio’s opDNA® template

Blanka Awtani 07/08/2025 Blanka Awtani 07/08/2025

4basebio synthetic DNA powers tier 1 pharma IND filing for mRNA vaccine

07 AUG 2025

Press release: A tier one pharmaceutical partner received FDA approval for their IND application for an mRNA vaccine developed using 4basebio’s synthetic DNA

Blanka Awtani 28/07/2025 Blanka Awtani 28/07/2025

4basebio strengthens board with strategic appointment of biopharma leader Dr. Manja Boerman

28 JUL 2025

Press release: 4basebio appoints Dr. Manja Boerman to its Board of Directors

Blanka Awtani 07/07/2025 Blanka Awtani 07/07/2025

Influenza Research Consortium announces £1.2 million (C$2.2 million) in funding for the development of a novel broad-spectrum vaccine

07 JUL 2025

Press release: 4basebio plc, ConserV Bioscience Limited, Pegasus Biotech, the University of Leicester, and the National Research Council of Canada (NRC) receive funding to develop and manufacture a broadly protective influenza vaccine